These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 3893600)
1. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome. Curson DA; Barnes TR; Bamber RW; Platt SD; Hirsch SR; Duffy JC Br J Psychiatry; 1985 May; 146():474-80. PubMed ID: 3893600 [TBL] [Abstract][Full Text] [Related]
2. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression. Curson DA; Barnes TR; Bamber RW; Platt SD; Hirsch SR; Duffy JC Br J Psychiatry; 1985 May; 146():469-74. PubMed ID: 3893599 [TBL] [Abstract][Full Text] [Related]
3. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic. Curson DA; Barnes TR; Bamber RW; Platt SD; Hirsch SR; Duffy JC Br J Psychiatry; 1985 May; 146():464-9. PubMed ID: 3893598 [TBL] [Abstract][Full Text] [Related]
4. Depot fluphenazine decanoate and enanthate for schizophrenia. David A; Adams CE; Eisenbruch M; Quraishi S; Rathbone J Cochrane Database Syst Rev; 2005 Jan; (1):CD000307. PubMed ID: 15674872 [TBL] [Abstract][Full Text] [Related]
5. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. Odejide OA; Aderounmu AF J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630 [TBL] [Abstract][Full Text] [Related]
6. [Results of long-term treatment with depot neuroleptics in schizophrenic patients]. Klein A; Ehle G Psychiatr Neurol Med Psychol (Leipz); 1988 Mar; 40(3):159-67. PubMed ID: 3132729 [TBL] [Abstract][Full Text] [Related]
7. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. Hirsch SR; Gaind R; Rohde PD; Stevens BC; Wing JK Br Med J; 1973 Mar; 1(5854):633-7. PubMed ID: 4571196 [TBL] [Abstract][Full Text] [Related]
8. The use of depot neuroleptics: clinical experience in the United States. Kane JM J Clin Psychiatry; 1984 May; 45(5 Pt 2):5-12. PubMed ID: 6370987 [TBL] [Abstract][Full Text] [Related]
9. Low dose medication strategies in the maintenance treatment of schizophrenia. Kane JM Schizophr Bull; 1983; 9(4):528-32. PubMed ID: 6140751 [TBL] [Abstract][Full Text] [Related]
10. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Johnson DA; Pasterski G; Ludlow JM; Street K; Taylor RD Acta Psychiatr Scand; 1983 May; 67(5):339-52. PubMed ID: 6135298 [TBL] [Abstract][Full Text] [Related]
12. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review. Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334 [TBL] [Abstract][Full Text] [Related]
13. Bromperidol decanoate (depot) for schizophrenia. Purgato M; Adams CE Cochrane Database Syst Rev; 2011 Sep; (9):CD001719. PubMed ID: 21901678 [TBL] [Abstract][Full Text] [Related]
14. Depot bromperidol decanoate for schizophrenia. Wong D; Adams CE; David A; Quraishi SN Cochrane Database Syst Rev; 2004; (3):CD001719. PubMed ID: 15266450 [TBL] [Abstract][Full Text] [Related]
15. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study. Levine J; Schooler NR; Severe J; Escobar J; Gelenberg A; Mandel M; Sovner R; Steinbook R Adv Biochem Psychopharmacol; 1980; 24():483-93. PubMed ID: 6996445 [No Abstract] [Full Text] [Related]
16. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Gitlin M; Nuechterlein K; Subotnik KL; Ventura J; Mintz J; Fogelson DL; Bartzokis G; Aravagiri M Am J Psychiatry; 2001 Nov; 158(11):1835-42. PubMed ID: 11691689 [TBL] [Abstract][Full Text] [Related]
17. The dysphoric syndrome in schizophrenia and its implications for relapse. Hirsch SR; Jolley AG Br J Psychiatry Suppl; 1989 Jul; (5):46-50. PubMed ID: 2690890 [No Abstract] [Full Text] [Related]
18. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Leong OK; Wong KE; Tay WK; Gill RC Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796 [TBL] [Abstract][Full Text] [Related]
19. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Schooler NR; Keith SJ; Severe JB; Matthews SM; Bellack AS; Glick ID; Hargreaves WA; Kane JM; Ninan PT; Frances A; Jacobs M; Lieberman JA; Mance R; Simpson GM; Woerner MG Arch Gen Psychiatry; 1997 May; 54(5):453-63. PubMed ID: 9152099 [TBL] [Abstract][Full Text] [Related]
20. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities. Citrome L; Jaffe A; Levine J Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]